Iron: The Secret Ingredient Breaking PARPi Resistance-Reference-Cited by-同舟云学术

Iron: The Secret Ingredient Breaking PARPi Resistance

Published:2024-08-02 Issue:8 Volume:14 Page:1372-1374
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:

Author:

Alborzinia Hamed¹²^ORCID,Friedmann Angeli José Pedro³^ORCID

Affiliation:

1. Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany. 1

2. Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany. 2

3. Rudolf Virchow Zentrum, Center for Integrative and Translational Bioimaging, Julius-Maximilians-University Würzburg, Würzburg, Germany. 3

Abstract

Summary: PARP inhibitors (PARPi) are used as a first-line treatment option for cancers with BRCA1/2 mutations, yet a significant number of patients show a limited response to these agents. In the present study, Lei and colleagues demonstrate that PARPi promote increased ferroptosis sensitivity and this can be exploited therapeutically to improve the response to PARPi, marking an important therapeutic concept to exploit ferroptosis-based strategies in clinical settings. See related article by Lei et al., p. 1476 (2).

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerdiscovery/article-pdf/14/8/1372/3477374/cd-24-0775.pdf

Reference10 articles.

1. Understanding and overcoming resistance to PARP inhibitors in cancer therapy;Dias;Nat Rev Clin Oncol,2021

2. BRCA1-mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP co-inhibition in BRCA1-deficient cancers;Lei;Cancer Disc,2024

3. Ferroptosis: mechanisms and implications for cancer development and therapy response;Dos Santos;Trends Cell Biol,2023

4. 7-Dehydrocholesterol is an endogenous suppressor of ferroptosis;Freitas;Nature,2024

5. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma;Alborzinia;EMBO Mol Med,2023